Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03239145 · OUTCOME

Maximum Tolerated Dose (MTD) of Trebananib

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg/kg
Interval / dispersion
Not reported
Time frame
3 weeks

What was measured

MTD will be defined as the dose level at which fewer than one-third of participants experience a dose-limiting toxicity attributable to pembrolizumab and trebananib, as determined using a standard 3+3 dose-escalation design.

Analysis population: This analysis applies only to patients who were enrolled and treated during the dose-escalation period.

Groups in this outcome

[Dose Escalation Dose Level I and Dose Level II] Pembrolizumab + Trebananib

Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 15 mg/kg or 30mg/kg weekly.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
[Dose Escalation Dose Level I and Dose Level II] Pembrolizumab + Trebananib6

Reported measurements

Source class 1
Values in mg/kg · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
[Dose Escalation Dose Level I and Dose Level II] Pembrolizumab + Trebananib30Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        30
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
MTD will be defined as the dose level at which fewer than one-third of participants experience a dose-limiting toxicity attributable to pembrolizumab and trebananib, as determined using a standard 3+3 dose-escalation design.
groups
  1. description
    Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 15 mg/kg or 30mg/kg weekly.
    id
    OG000
    title
    [Dose Escalation Dose Level I and Dose Level II] Pembrolizumab + Trebananib
param Type
NUMBER
population Description
This analysis applies only to patients who were enrolled and treated during the dose-escalation period.
reporting Status
POSTED
time Frame
3 weeks
title
Maximum Tolerated Dose (MTD) of Trebananib
type
PRIMARY
unit Of Measure
mg/kg

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice